Navigation Links
PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
Date:4/28/2009

ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it will be hosting a conference call for investors on Wednesday, April 29th beginning at 4:30 p.m. E.T., to review the status of its rPA anthrax vaccine program.

The dial-in number within the United States is 866-788-0540. The dial-in number for international callers is 857-350-1678. The participant passcode is 82129094.

A replay of the conference call will be available for 30 days, beginning at approximately 7:30 p.m. Eastern Time on Wednesday, April 29, 2009 until approximately 11:59 p.m. Eastern Time on May 29, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 53903666.

The conference call will also be webcast and can be accessed from the company's website at www.pharmathene.com. A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

    Contact:
    Stacey Jurchison
    PharmAthene, Inc.
    Phone: 410-269-2610
    Stacey.Jurchison@PharmAthene.com


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
2. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
3. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
4. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
5. MedNet Solutions to Share Industry Expertise at the 13th Annual EDC & Beyond Conference in Orlando, FL
6. Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
7. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
8. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
9. NewCardio Leadership to Present Two Abstracts at ISCE Conference
10. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
11. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... TAMPA, Fla. , Feb. 22, 2017  Corin ... Shoulder System, a device used to treat patients with ... form of shoulder arthritis. The condition, known as cuff ... arm and shoulder. The Humelock Reversed ... privately-held upper extremities technology company based near ...
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Pipeline Review, 2016" report to their offering. ... Dermatological conditions ... and approximately one-third of the US population suffers from at ... majority of the dermatology market has remained saturated with established ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By ... Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering. ... The ... growth during 2016-2022 This report provides a detailed ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 2017 , ... Using the power of the internet, IdrisArkette.com has managed to ... period of just 24 months, thousands of individuals interested in a medical procedure managed ... “The internet is not getting quieter. In fact it’s becoming noisier by the day. ...
(Date:2/22/2017)... Delray Beach, FL (PRWEB) , ... February 22, 2017 , ... ... celebrity Wrestling Legend Kurt Angle, is now available on the App Store ... solutions and award-winning mobile apps for the addiction and recovery industry, partnered with Angle ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a ... of a small number of neurosurgeons in Michigan performing minimally invasive back surgery ...
(Date:2/22/2017)... PA (PRWEB) , ... February 22, 2017 , ... A ... some people seem to derive a heart-protective benefit from eating soy foods, while others ... , Japanese men who are able to produce equol—a substance made by some types ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent ... those report that family members or friends have also commented about their poor ... loss wear hearing aids. One reason, suggested by 89 percent of American respondents, ...
Breaking Medicine News(10 mins):